GlassScriptPhysician profile
Steven J Sheris
NPI 1629062187
$11,075.08
in general payments reported to CMS, 2019-2025
30 companies · $519 in 2025
The $519 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $4,458 · 2021: $124 · 2022: $355 · 2023: $4,826 · 2024: $387 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,404 · Food and Beverage: $1,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,403.74 |
| Food and Beverage | $1,329.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $9,019.63 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $451.05 | 2022-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $219.83 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $214.08 | 2019-2024 | |
| Amgen INC. | $208.83 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $170.11 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $128.25 | 2022-2025 | Verquvo |
| Irhythm Technologies, INC. | $87.18 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Medtronic Vascular, INC. | $62.17 | 2019 | |
| Novo Nordisk INC | $55.79 | 2025 | Wegovy |
| Althera Pharmaceuticals LLC | $50.46 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.53 | 2020-2025 | Lifevest |
| Amarin Pharma, INC. | $39.57 | 2019-2020 | |
| Baxter Healthcare | $36.81 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Astrazeneca Pharmaceuticals LP | $30.78 | 2024-2025 | Farxiga |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $30.71 | 2024 | Arcalyst |
| Abbott Laboratories | $25.62 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $24.83 | 2025 | Eliquis |
| Mckesson Corporation | $20.13 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.07 | 2025 | |
| Bridgebio Pharma, INC. | $16.46 | 2025 | Attruby |
| Masimo Corporation | $15.93 | 2019 | |
| Cleerly, INC. | $14.96 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Kowa Pharmaceuticals America, INC. | $14.89 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $14.42 | 2022 | |
| Philips North America LLC | $14.07 | 2025 | Extended Holter |
| Medicure Pharma INC. | $13.74 | 2024 | Zypitamag |
| Esperion Therapeutics, INC. | $13.51 | 2021 | |
| Boston Scientific Corporation | $12.97 | 2019 | |
| Cvrx, INC. | $9.70 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Sheris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.